Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00005963 · ClinicalTrials.gov registry record · Phase 2

Docetaxel and Carboplatin in Treating Women With Metastatic Breast Cancer

A Phase 2 study, sponsored by Alliance for Clinical Trials in Oncology.

Completed
Registry status
Phase 2
Development phase
53
Enrollment target

NCT00005963 is a Phase 2 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 53 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00005963, a Phase 2 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.

COMPLETED
Registry status
Phase 2
Development phase
53 participants
Enrollment target

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining docetaxel and carboplatin in treating women who have metastatic breast cancer.

Interventions

  • DRUG carboplatin
  • DRUG docetaxel

Trial Details

FieldValue
Enrollment Target 53 participants
Start Date 2000-11
Est. Completion 2009-01
Phase Phase 2

What the Registry Record Tells You About NCT00005963

The ClinicalTrials.gov registry entry for NCT00005963 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which carboplatin is the first listed.

NCT00005963 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00005963 about?

NCT00005963 is a clinical study titled "Docetaxel and Carboplatin in Treating Women With Metastatic Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining docetaxel and carboplatin in treating women wh...

What is the current status of trial NCT00005963?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2000-11. Estimated completion is 2009-01.

What interventions are being tested in trial NCT00005963?

The interventions under investigation include: carboplatin (DRUG), docetaxel (DRUG).

Who is sponsoring clinical trial NCT00005963?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.